Stock Events

Stock Events

Evotec 

€5.06
368
-€0.06-1.08% Today

Statistics

Day High
5.09
Day Low
5.05
52W High
8.35
52W Low
4.11
Volume
2,500
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-0.58
-0.1
0.39
0.87
Expected EPS
-0.28306565
Actual EPS
N/A

Financials

-24.6%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
796.97MRevenue
-196.08MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EVT.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.7B
CRISPR Therapeutics is involved in gene editing, a field that overlaps with Evotec's drug discovery platforms, making them direct competitors in the biotech innovation space.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.45B
Vertex Pharmaceuticals focuses on creating new treatments for serious diseases, directly competing with Evotec's drug discovery and development services.
Novartis
NVS
Mkt Cap280.79B
Novartis is a large pharmaceutical company that competes with Evotec in the drug discovery and development sector, particularly in the development of novel therapeutics.
Gilead Sciences
GILD
Mkt Cap161.85B
Gilead Sciences is a biopharmaceutical company that competes with Evotec in the area of drug discovery, development, and commercialization, especially in the fields of antiviral drugs.
AMGEN
AMGN
Mkt Cap185.74B
Amgen is a biotechnology firm focusing on human therapeutics, competing with Evotec in drug discovery and development, particularly in the biotech sector.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.46B
Regeneron Pharmaceuticals is known for its innovation in biopharmaceuticals, competing with Evotec in drug discovery and development, especially in the area of monoclonal antibodies.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.28B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and rare genetic diseases, competing with Evotec in the niche market of rare diseases drug discovery.
Alnylam Pharmaceuticals
ALNY
Mkt Cap40.77B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, competing with Evotec in the development of novel RNA-based therapies.
Beam Therapeutics
BEAM
Mkt Cap2.79B
Beam Therapeutics competes with Evotec in the cutting-edge field of gene editing, specifically using base editing technology to develop precision genetic medicines.

About

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Show more...
CEO
Dr. Christian Wojczewski Ph.D.
Employees
4467
Country
Germany
ISIN
DE0005664809
WKN
000566480

Listings

MU
DE
EVT.MU
STU
DE
EVT.STU
STU
DE
EVTA.STU
MU
DE
EVTA.MU

0 Comments

Share your thoughts

FAQ

What is Evotec stock price today?▼
The current price of EVT.F is €5.06 EUR — it has decreased by -1.08% in the past 24 hours. Watch Evotec stock price performance more closely on the chart.
What is Evotec stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Evotec stocks are traded under the ticker EVT.F.
Is Evotec stock price growing?▼
EVT.F stock has fallen by -10.2% compared to the previous week, the month change is a +15.82% rise, over the last year Evotec has showed a -32.01% decrease.
When is the next Evotec earnings date?▼
Evotec is going to release the next earnings report on May 06, 2026.
What were Evotec earnings last quarter?▼
EVT.F earnings for the last quarter are -0.24 EUR per share, whereas the estimation was -0.14 EUR resulting in a -81.13% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Evotec revenue for the last year?▼
Evotec revenue for the last year amounts to 796.97M EUR.
What is Evotec net income for the last year?▼
EVT.F net income for the last year is -196.08M EUR.
How many employees does Evotec have?▼
As of April 29, 2026, the company has 4,467 employees.
In which sector is Evotec located?▼
Evotec operates in the Health & Wellness sector.
When did Evotec complete a stock split?▼
The last stock split for Evotec was on October 20, 2021 with a ratio of 4:1.
Where is Evotec headquartered?▼
Evotec is headquartered in Hamburg, Germany.